PharmaResearch's tissue regeneration product, Conjuran, not only demonstrated significant pain reduction but also maintained the effect at six months post-dose in a multicenter collaborative clinical trial.

PharmaResearch announced on April 28 that Prof. Kang Seung-Baik of Boramae Hospital, Seoul National University and Prof. Choi Won Chul of CHA Bundang Medical Center presented the results of three Conjuran clinical trials at the recent Korean Orthopaedic Association’s spring conference.

Clinical results showed non-inferiority or some improvement in outcomes for Conjuran in most data comparing Conjuran with HA3 formulations.

Patients with severe KL-grade 4 degenerative arthritis were included in this study.

Pain reduction (54.2% change) was maintained at 6 months after treatment with Conjuran, and the treatment’s safety demonstrated with an adverse event rate of 0.55% (3 of 546 events).

These studies will be published in the June issue of the Journal of the Korean Orthopaedic Association.

PharmaResearch said, “It is significant that the clinically proven pain reduction effects of Conjuran have been presented at the Korean Orthopaedic Association’s conference, and we will continue to strive to make Conjuran as a solution for knee pain by promoting it based on data from clinical trials as the original product for the PN joint cavity."

[WIKI KOREA=Cho Eun, Reporter]

choeun@wikileaks-kr.org

Cho Eun, Reporter 다른기사 보기

• facebook
• 트위터
• 카카오톡
• 네이버블로그
• 유튜브